Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) PT at $10.50

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) have been given a consensus recommendation of “Hold” by the five ratings firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $11.20.

Separately, BMO Capital Markets reissued an “outperform” rating and set a $20.00 target price on shares of C4 Therapeutics in a report on Tuesday, August 6th.

C4 Therapeutics Price Performance

CCCC stock opened at $5.61 on Thursday. The company has a fifty day moving average price of $6.00 and a two-hundred day moving average price of $5.79. C4 Therapeutics has a one year low of $1.06 and a one year high of $11.88. The stock has a market cap of $389.00 million, a price-to-earnings ratio of -2.95 and a beta of 3.04.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. C4 Therapeutics had a negative net margin of 367.17% and a negative return on equity of 44.60%. The firm had revenue of $12.01 million during the quarter, compared to analysts’ expectations of $6.88 million. Research analysts anticipate that C4 Therapeutics will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On C4 Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Headlands Technologies LLC acquired a new position in C4 Therapeutics in the second quarter valued at about $45,000. B. Riley Wealth Advisors Inc. acquired a new position in C4 Therapeutics in the second quarter valued at about $51,000. Cornercap Investment Counsel Inc. acquired a new position in C4 Therapeutics in the second quarter valued at about $125,000. Entropy Technologies LP acquired a new position in C4 Therapeutics in the first quarter valued at about $126,000. Finally, SG Americas Securities LLC acquired a new position in C4 Therapeutics in the third quarter valued at about $142,000. Institutional investors and hedge funds own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.